Onderneming Lexagene Holdings Inc Toronto S.E.
Aandelen
WEY
CA52886L1031
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
CAD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Genetic Analyzer
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +21,70% |
Verkoop per regio
CAD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +21,70% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jack Regan
CEO | Chief Executive Officer | - | 26-04-07 |
Jeffrey Mitchell
DFI | Director of Finance/CFO | - | 01-03-18 |
Steven Armstrong
COO | Chief Operating Officer | - | 24-03-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Joseph P. Caruso
BRD | Director/Board Member | 65 | 18-06-18 |
Jack Regan
CEO | Chief Executive Officer | - | 26-04-07 |
Tom Slezak
BRD | Director/Board Member | - | 12-10-16 |
Jane Sykes
BRD | Director/Board Member | - | 15-11-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 140 740 255 | 115 621 362 ( 82,15 %) | 0 | 82,15 % |
Bedrijfsgegevens
Lexagene Holdings, Inc.
500 Cummings Center Suite 4550
01915, Beverly
+800 215 1824
http://www.lexagene.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-31,90% | 9,3 mld. | |
-6,25% | 3,1 mld. | |
+25,95% | 2,87 mld. | |
-13,96% | 2,17 mld. | |
-16,83% | 1,75 mld. | |
+72,82% | 1,5 mld. | |
+29,17% | 807 mln. | |
-2,62% | 759 mln. | |
-26,33% | 532 mln. |